Latest Conference Articles

Dr. Ross on the Treatment of Liver Metastasis in Melanoma

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses treatment for liver metastasis in patients with melanoma.

Weighing Efficacy and Tolerability for Adjuvant Ipilimumab in Advanced Melanoma

Treatment with ipilimumab has been shown to improve overall survival; however, this efficacy often comes with toxicity.

Adjuvant PD-1 Inhibition on Horizon in Melanoma

Several clinical trials are examining the use of adjuvant PD-1 inhibition for patients with melanoma, with a potential new standard of care on the horizon for those at high risk of recurrence following resection.

Expert Discusses Tumor Location and Mutational Status in CRC

Julien Taieb, MD, discusses the prognostic value of primary tumor location in colon cancer.

Weber Says Pembrolizumab/Epacadostat Could Become Frontline Treatment of Choice in Melanoma

Jeffrey S. Weber, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of brain metastases, the tolerability of the combination of ipilimumab and talimogene laherparepvec (Imlygic; T-VEC), and what is next on the horizon for pembrolizumab (Keytruda).

Expert Highlights Impressive Long-Term Activity With BRAF/MEK Combos in Melanoma

Melissa A. Wilson, MD, PhD, discussed the promising results with BRAF/MEK inhibitor combinations in melanoma and what ongoing studies have the potential to alter the landscape again.

Expert Discusses Adjuvant Ipilimumab Regimens in Melanoma

Jean Jacques Grob, MD, PhD, discusses the efficacy and tolerability of different doses of ipilimumab given in the adjuvant setting for patients with melanoma.

HA Levels Predict PEGPH20 Response in Metastatic Pancreatic Cancer

The addition of pegvorhyaluronidase alfa (PEGPH20) to standard nab-paclitaxel/gemcitabine improved progression-free survival over standard therapy in patients with metastatic pancreatic ductal adenocarcinoma.

Dr. Hendifar on the HALO-202 Study in Metastatic Pancreatic Ductal Adenocarcinoma

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses HALO-202 in metastatic pancreatic ductal adenocarcinoma.

Dr. Bruix Discusses the Updated Findings of the RESORCE Trial in HCC

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the updated findings of the RESORCE Trial in hepatocellular carcinoma.

AM0010 Plus FOLFOX Shows Promise in Metastatic Pancreatic Cancer

Combination therapy with AM0010, a PEGylated human interleukein (IL)-10, plus fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) demonstrated encouraging clinical activity in metastatic pancreatic ductal adenocarcinoma.

Dr. Stratigos on the Prevention of Melanoma

Alexander J. Stratigos, MD, University of Athens Medical School, discusses prevention techniques for melanoma.

Dr. Ascierto on Sequencing of Targeted Therapies for Melanoma

Paolo A. Ascierto, MD, National Tumour Institutue “Fondazione G. Pascale,” Unit of Melanoma, Naples, Italy, discusses the sequencing of targeted therapies for patients with melanoma.

Chemotherapy-Free Triplet Achieves 100% Response Rates in 3 Lymphoma Subtypes

The first known trial of combined ublituximab (TG-1101), ibrutinib (Imbruvica), and umbralisib (TGR-1202) showed that the combination was well tolerated and had activity across heavily pretreated patients with high-risk B-cell malignancies.

Ibrutinib/Venetoclax Yields Dramatic Blood Response in Patients With Relapsed/Refractory CLL

Combination ibrutinib (Imbruvica) and venetoclax (Venclexta) set the bar high and aims to achieve eradication of minimal residual disease within a year of treatment in patients with relapsed or refractory chronic lymphocytic leukemia.

Combination of Obinutuzumab and CC-122 Demonstrates Response in R/R Non-Hodgkin Lymphoma

The combination of obinutuzumab and CC-122 was well tolerated and demonstrated promising response rates and durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

Polatuzumab Vedotin Demonstrates Durable Reponses in Follicular Lymphoma, DLBCL

Matthew J. Matasar, MD, discusses the potential of polatuzumab vedotin in patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.

Dr. Ravandi on Vadastuximab Talirine Plus Hypomethylating Agents in AML

Farhad Ravandi-Kashani, MD, professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses vadastuximab talirine plus hypomethylating agents in acute myeloid leukemia.

Dr. Smith Discusses CD19 CAR T-Cell Therapy in B-ALL

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses CD19 (19-28Z) CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

CTL019 CAR T-Cell Therapy Strides Towards Approval in Pediatric and Young Adult Patients With ALL

CTL019, an investigational chimeric antigen receptor T-cell therapy, demonstrated high response rates and a manageable safety profile in pediatric and young adult patients with relapsed and/or refractory acute lymphoblastic leukemia.

Dr. Wang Discusses FLT3 Mutations in AML

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses FLT3 mutations in acute myeloid leukemia.

Dr. Perales on Remaining Questions With CAR T-Cell Therapy in Hematologic Malignancies

Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses the remaining questions with CAR T-cell therapy in hematologic malignancies.

Dr. Eskelund on Study of TP53 Mutations in Mantle Cell Lymphoma

Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses a study of TP53 mutations in mantle cell lymphoma.

Cerdulatinib Shows Promise in Relapsed/Refractory NHL

Paul A. Hamlin, MD, discusses his research with cerdulatinib in patients with certain types of non-Hodgkin lymphoma.

Comparison of Induction Therapies Prior to ASCT Favors Novel Quadruple Over Triplet Regimens

Results from the phase III Myeloma XI study showed that patients with myeloma had deeper responses after induction and after allo-stem cell transplantation with outpatient-delivered quadruplet therapy than with sequential immunomodulatory triplet combinations.

Ixazomib Maintenance Shows Robust Activity in Multiple Myeloma

Patients with newly-diagnosed multiple myeloma who did not elect to undergo stem cell transplant but remained on single agent ixazomib maintenance fared as well as those who received SCT.

Dr. Hiddemann on Updated Results of Immunochemotherapy Study in Follicular Lymphoma

Wolfgang Hiddemann, MD, PhD, director of the Department of Hematology and Oncology, University of Munich, discusses the updated results of an immunochemotherapy study in follicular lymphoma.

Dr. Hamlin on Study of Cerdulatinib in Non-Hodgkin Lymphoma

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a study of cerdulatinib in non-Hodgkin lymphoma.

Response Rate Hits 100% for bb2121 in Multiple Myeloma

All patients with multiple myeloma in a phase I study showed a response following treatment with an active dose of bb2121, an investigational anti–BCMA CAR T-cell construct.

Biomarkers Emerge for Severe Neurotoxicity Risk After CAR T-Cell Therapy

Investigators reported the characterization of early clinical and serum biomarkers that may identify specific patients with ALL being treated with 19-28z chimeric antigen receptor T cells needing an early intervention to mitigate the development of severe neurotoxicity.